Biomea Fusion (BMEA) – Analysts’ Weekly Ratings Changes

Several analysts have recently updated their ratings and price targets for Biomea Fusion (NASDAQ: BMEA):

• 12/17/2024 – Biomea Fusion had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $128.00 price target on the stock.
• 12/16/2024 – Biomea Fusion had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
• 12/10/2024 – Biomea Fusion had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
• 12/10/2024 – Biomea Fusion had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $128.00 price target on the stock.
• 11/21/2024 – Biomea Fusion had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
• 11/19/2024 – Biomea Fusion had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $128.00 price target on the stock.
• 10/31/2024 – Biomea Fusion had its price target raised by analysts at Piper Sandler from $10.00 to $19.00. They now have an “overweight” rating on the stock.
• 10/31/2024 – Biomea Fusion had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
• 10/30/2024 – Biomea Fusion had its price target raised by analysts at Barclays PLC from $9.00 to $11.00. They now have an “equal weight” rating on the stock.

Biomea Fusion Stock Performance

Shares of Biomea Fusion stock opened at $4.03 on Tuesday. The company’s 50 day moving average price is $7.97 and its 200-day moving average price is $7.11. Biomea Fusion, Inc. has a 52-week low of $3.61 and a 52-week high of $20.21. The stock has a market capitalization of $146.04 million, a price-to-earnings ratio of -1.00 and a beta of -0.53.

Biomea Fusion (NASDAQ:BMEA) last announced its earnings results on Tuesday, October 29th. The company reported ($0.91) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.03. As a group, equities research analysts forecast that Biomea Fusion, Inc. will post -3.93 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Michael J.M. Hitchcock purchased 10,000 shares of the company’s stock in a transaction dated Monday, September 30th. The shares were purchased at an average cost of $10.06 per share, for a total transaction of $100,600.00. Following the purchase, the director now directly owns 15,000 shares in the company, valued at approximately $150,900. This represents a 200.00 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 27.57% of the company’s stock.

Hedge Funds Weigh In On Biomea Fusion

Institutional investors have recently bought and sold shares of the stock. Point72 Asia Singapore Pte. Ltd. bought a new stake in Biomea Fusion during the second quarter valued at about $36,000. Scientech Research LLC purchased a new position in Biomea Fusion in the second quarter worth about $46,000. DRW Securities LLC bought a new position in shares of Biomea Fusion during the 2nd quarter valued at approximately $55,000. China Universal Asset Management Co. Ltd. increased its position in Biomea Fusion by 64.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 6,964 shares of the company’s stock valued at $70,000 after acquiring an additional 2,741 shares during the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new stake in Biomea Fusion in the 2nd quarter worth about $109,000. 96.72% of the stock is owned by institutional investors.

Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.